<DOC>
	<DOC>NCT00826371</DOC>
	<brief_summary>The purpose of the study is to provide efficacy and safety data for monthly ranibizumab 0.5 mg intravitreal injections in Chinese patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). The study results will support the regulatory submission in China to make ranibizumab available for clinical use.</brief_summary>
	<brief_title>Evaluation of Safety and Efficacy of Once Monthly Ranibizumab Injections in Chinese Patients With Wet Age Related Macular Degeneration (AMD) Patients</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Male or female Chinese patients 50 years of age or greater. Patients with primary or recurrent subfoveal CNV secondary to AMD. Patients who have a BCVA score from 73 to 24 characters in the study eye. Active, or history of, ocular inflammation or infection in the study eye within the last 30 days. Uncontrolled glaucoma in the study eye. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>AMD</keyword>
	<keyword>Ranibizumab</keyword>
</DOC>